CompletedNot Applicable

Semaglutide and Intestinal Iron Absorption

Croatia51 participantsStarted 2023-11-01

Plain-language summary

Semaglutide belongs to a group of long-acting glucagon-like peptide 1 receptor agonists (GLP-1). Disorders in iron absorption have been linked to numerous medication, dietary, and nutrient interactions thus far. The study aimed to determine whether there is an effect of concomitant parenteral administration of semaglutide and oral iron preparations on iron absorption in patients with type 2 diabetes (T2DM).

Who can participate

Age range45 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * T2DM patients * ages between 45 and 65 * with poorly managed T2DM (HbA1c ≥ 7%) * who are candidates for treatment intensification and beginning of parenterally administered semaglutide Exclusion Criteria: * hypersensitivity to GLP-1 RAs, * adequately controlled with current glucose-lowering medications, * already treated with GLP-1 RA, * type 1 diabetes mellitus or any other form of diabetes, * hemochromatosis, * iron deficiency anaemia, * sideropaenia, * severe chronic illnesses, * malignant neoplasms of any site, * chronic infectious diseases, * chronic rheumatic inflammatory diseases, * malabsorption syndrome, * inflammatory bowel disease, * history of gastrointestinal tract reduction surgery, * medications that interfere with absorption, * perimenopausal women

What they're measuring

General objective

Timeframe: 10 weeks

Trial details

NCT IDNCT06629688

SponsorUniversity Hospital Dubrava

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-01

View on ClinicalTrials.gov More Diabetes Mellitus Type 2 trials